Medella Health Limited

Medella Health Limited specializes in respiratory therapy devices. Their primary product, the FLOWpresso, is designed for controlled inhalation or nebulization of medications, helping deliver treatments directly to the lungs.

Medella Health Limited is headquartered in the United States. The company’s location is relevant for regulatory oversight and compliance, as it operates under FDA jurisdiction.

The FLOWpresso, Medella Health Limited’s example device, is classified as a Class II medical device by the FDA. This classification indicates moderate regulatory controls, including performance standards and post-market surveillance, to ensure safety and effectiveness for its intended use in respiratory therapy.

The FLOWpresso is documented in the FDA’s 510(k) clearance registry, which tracks devices that have undergone premarket notification review to demonstrate substantial equivalence to a legally marketed predicate device. This registry helps healthcare providers and regulators verify compliance and authorization status.